AU2014274586B2

AU2014274586B2 - Nucleic acids and proteins from streptococcus groups A & B

Info

Publication number: AU2014274586B2
Application number: AU2014274586A
Authority: AU
Inventors: Claire Fraser; Guido Grandi; Vega Masignani; Maria Scarselli; John Telford; Hervé TETTELIN
Original assignee: Novartis AG
Current assignee: Novartis AG; J Craig Venter Institute Inc
Priority date: 2000-10-27
Filing date: 2014-12-19
Publication date: 2017-01-05
Anticipated expiration: 2021-10-29
Also published as: AU2012200299A1; AU2014274586A1; AU2012200299B2

Abstract

The invention provides proteins from group B streptococcus (Streptococcus agalactia) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Description

2014274586 19 Dec 2014

EDITORIAL NOTE 2014274586

There are 3024 pages of description.

The accepted description can be found as physical media in the basement.

Claims

The claims defining the invention are as follows:

1. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of: (a) nucleic acid encoding a protein comprising SEQ ID NO: 4212, but not comprising SEQ ID NO: 4211; (b) a mutant sequence having 50% or greater sequence identity to SEQ ID NO: 4211; or (c) a sequence encoding a fusion protein comprising a protein which has 50% or greater sequence identity to SEQ ID NO: 4212.
2. The nucleic acid molecule of claim 1, wherein the nucleic acid sequence having 50% or greater sequence identity to SEQ ID NO: 4211, but not comprising SEQ ID NO: 4211, encodes a functional mutant or homolog of SEQ ID NO: 4212.
3. A vector comprising a nucleic acid sequence selected from the group consisting of (i) the nucleic acid sequence of claim 1 or 2, (ii) a nucleic acid sequence comprising SEQ ID NO: 4211, (iii) a nucleic acid sequence encoding a protein comprising a fragment of 100 or more consecutive nucleotides of SEQ ID NO: 4212; or (iv) a nucleic acid sequence encoding a fusion protein comprising a sequence which has at least 90% sequence identity to SEQ ID NO: 4212.
4. The vector of claim 3, further comprising a promoter.
5. The vector of claim 4, wherein the promoter is operably linked to the nucleic acid sequence of any one of claims 1 to 3.
6. The vector of claim 4 or 5, wherein the promoter is a mammalian promoter.
7. The vector of any one of claims 4 to 6, wherein the promoter is selected from the group consisting of the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and a sequence derived from a non-viral gene.
8. The vector of any one of claims 4 to 7, wherein the promoter is inducible.
9. The vector of any one of claims 4 to 7, wherein the promoter is constitutive.
10. The vector of any one of claims 3 to 9, wherein the vector is selected from the group consisting of a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes viral vector, and an alphavirus vector.
11. An isolated protein selected from the group consisting of: (a) a protein comprising the amino acid sequence SEQ ID NO: 4212; (b) a protein having 50% or greater sequence identity to (a); (c) a protein comprising the amino acid sequence of SEQ ED NO: 4212, produced by recombinant expression in a cell other than a Streptococcus pyogenes cell; (d) a functional mutant or homolog of SEQ ID NO: 4212, with at least 90% sequence identity to SEQ ID NO: 4212; (e) a protein comprising a fragment of 7 or more, such as 100 or more, consecutive amino acids of SEQ ID NO: 4212; (f) a hybrid protein represented by the formula NH2-A-[-X-L-]„-B-COOH, wherein X is the amino acid sequence SEQ ED NO:4212, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer, wherein n is greater than 1; (g) a fusion protein comprising a polypeptide comprising a sequence which has at least 90% sequence identity to SEQ ID NO: 4212; and (h) an antibody that binds a protein comprising SEQ ID NO: 4212.
12. The protein of claim 11, wherein the protein is an antibody and wherein the antibody is monoclonal, chimeric, humanized or fully human.
13. The protein of claim 12, further comprising a detectible label.
14. The protein of claim 11, wherein the protein is a fusion protein comprising a polypeptide comprising a sequence which has at least 90% sequence identity to SEQ ID NO: 4212, and wherein the fusion protein comprises a histidine tag, a glutathione S-transferase (GST) tag, a signal sequence, or a leader sequence.
15. A cell comprising the nucleic acid of any of claims 1 to 2 or a nucleic acid comprising SEQ ID NO: 4211, the vector of any of claims 3 to 10 or the protein of any of claims 11 to 14.
16. The cell of claim 15, wherein the cell is a mammalian cell.
17. A composition comprising the nucleic acid of any of claims 1 to 2 or a nucleic acid comprising SEQ ID NO: 4211, the vector of claims 3 to 10, or the protein of any of claims 11 to 14, a pH buffering substance, and a pharmaceutically acceptable vehicle.
18. The composition of claim 17, wherein the composition comprises two or more proteins of claim 11, each protein selected from the group consisting of: (a) a protein comprising the amino acid sequence SEQ ID NO: 4212; (b) a protein having 50% or greater sequence identity to (a); and (c) a protein comprising a fragment of 7 or more consecutive amino acids from the amino acid sequence SEQ ID NO: 4212.
19. An in vitro method of inducing the expression of the protein of claim 11 in a mammalian cell, said method comprising introducing into the cell a nucleic acid encoding said protein.
20. The method of claim 19, wherein the nucleic acid encodes SEQ ED NO: 4212 and a protein comprising SEQ ED NO: 4212 is expressed.
21. The nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18, for use as a medicament.
22. The nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18, for use as a vaccine.
23. The nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18, for use in the manufacture of a medicament for treating or preventing a disease and/or infection caused by streptococcus.
24. A method of treating or preventing a disease and/or infection caused by streptococcus in a patient comprising administering to the patient the nucleic acid molecule of any of claims 1 or 2, the vector of any one of claims 3 to 10, the protein of any one of claims 11 to 14, the cell of claim 15 or 16, or the composition of claims 17 or 18.
25. A vector comprising a nucleic acid sequence encoding the isolated protein of claim 11.